Study of an oral medication for adults with non-transfusion-dependent thalassemia
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests an investigational oral medication (SNH-119014) in adults with non-transfusion-dependent thalassemia, which means they have anemia but don't need regular transfusions. It aims to see if the drug can safely help increase hemoglobin levels and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older
- You have been diagnosed with thalassemia and do not require regular blood transfusions
- Your hemoglobin level is 10 g/dL or lower during the screening period
- If you are a woman who can become pregnant, you must have a negative pregnancy test and agree to use approved birth control
- You have not had a heart attack, heart failure, or blood clots in the past 6 months
- You are not currently taking blood thinners or certain other medications (like luspatercept or hydroxyurea)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests the safety and possible benefits of an injection called HGI-001 for people with severe transfusion-dependent beta thalassemia. It may help by preparing you for stem cell transplant, but you must meet several health and lab criteria and be able to return often for follow-up tests.
This trial tests an oral medication called AND017 for people with beta-thalassemia. It aims to see if the drug can safely help reduce the need for blood transfusions or improve hemoglobin levels.
This early-phase trial studies HGI-002 to see if it’s safe and can help people with severe alpha thalassemia who need frequent blood transfusions. It also requires planning for a special treatment approach that includes busulfan pre-treatment and stem cell transplantation.
This trial tests if certain drugs can safely increase fetal hemoglobin (a type of hemoglobin that helps carry oxygen) in people with beta thalassemia major. It may offer a new way to manage the condition and reduce the need for transfusions.
This trial tests a one-time treatment that uses your own (autologous) stem cells that have been changed by gene methods, then returned to you to help manage transfusion-dependent beta-thalassemia. It aims to check safety and whether it can reduce the need for frequent blood transfusions or improve blood health.
This study tests whether a combination of two drugs, luspatercept and thalidomide, can help people with beta-thalassemia who need regular blood transfusions. It aims to reduce the number of transfusions needed.
Hear when a new Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.